|
Dec 26
|
HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 Elections
|
|
Dec 21
|
Here’s Why Teva Pharmaceutical Industries Limited (TEVA) Rose in Q3
|
|
Dec 15
|
My 5 Largest Portfolio Holdings for 2024
|
|
Dec 14
|
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
|
|
Dec 7
|
FTC warns pharma companies on excessive drug patenting
|
|
Dec 6
|
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
|
|
Nov 30
|
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
|
|
Nov 27
|
Teva Pharmaceutical upgraded to 'Buy' at UBS
|
|
Nov 27
|
Roku upgraded, Lucid Group downgraded: Wall Street's top analyst calls
|
|
Nov 27
|
Teva Pharmaceutical: Long-Term Cash Cow
|
|
Nov 27
|
Midday movers: Affirm, Amazon, and More
|
|
Nov 27
|
Roku raised to Buy, YPF extends gains following upgrade: 4 big analyst picks
|
|
Nov 8
|
Teva Pharma Makes A Bullish Move After Quarterly Beat, Business Separation Plans
|
|
Nov 8
|
Teva Pharmaceutical Industries Ltd (TEVA) Reports Q3 2023 Earnings and Raises Revenue Outlook
|
|
Nov 8
|
Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Israel’s Teva Lifts Outlook With War Not Curbing Drug Production
|
|
Nov 8
|
Teva Pharmaceutical Industries Ltd. (TEVA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Nov 8
|
UPDATE 3-Teva says Israel-Hamas war not hurting production, eyes growth in 2024
|
|
Nov 8
|
Teva says Israel-Hamas war not hurting production, eyes growth in 2024
|
|
Nov 8
|
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
|